These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 38819073

  • 1. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Mitsui Y, Okawa M, Hori S, Uetani M, Kasahara M, Yamabe F, Kobayashi H, Nagao K, Nakajima K.
    Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073
    [Abstract] [Full Text] [Related]

  • 2. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S, VESPER Trial Investigators.
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [Abstract] [Full Text] [Related]

  • 3. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W, Collaborators.
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [Abstract] [Full Text] [Related]

  • 4. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    Lee Y, Kim YS, Hong B, Cho YM, Lee JL.
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
    Cancer; 2015 Aug 01; 121(15):2586-93. PubMed ID: 25872978
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
    van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW.
    World J Urol; 2016 Feb 01; 34(2):157-62. PubMed ID: 26184106
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R.
    BMC Urol; 2020 Oct 14; 20(1):158. PubMed ID: 33054762
    [Abstract] [Full Text] [Related]

  • 8. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP.
    BJU Int; 2021 Nov 14; 128(5):607-614. PubMed ID: 33909949
    [Abstract] [Full Text] [Related]

  • 9. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
    Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulié M, Allory Y, Harter V, Culine S, VESPER Trial Investigators.
    J Clin Oncol; 2022 Jun 20; 40(18):2013-2022. PubMed ID: 35254888
    [Abstract] [Full Text] [Related]

  • 10. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
    Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S, VESPER Trial Investigators.
    Lancet Oncol; 2024 Feb 20; 25(2):255-264. PubMed ID: 38142702
    [Abstract] [Full Text] [Related]

  • 11. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H, Tsukamoto T, Shibata T, Masumori N, Fujimoto H, Hirao Y, Fujimoto K, Kitamura Y, Tomita Y, Tobisu K, Niwakawa M, Naito S, Eto M, Kakehi Y, Urologic Oncology Study Group of the Japan Clinical Oncology Group.
    Ann Oncol; 2014 Jun 20; 25(6):1192-8. PubMed ID: 24669010
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K, Obara W, Kato Y, Takata R, Tanji S, Fujioka T.
    Jpn J Clin Oncol; 2013 Feb 20; 43(2):193-9. PubMed ID: 23275643
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
    Okabe K, Shindo T, Maehana T, Nishiyama N, Hashimoto K, Itoh N, Takahashi A, Taguchi K, Tachiki H, Tanaka T, Masumori N.
    Jpn J Clin Oncol; 2018 Oct 01; 48(10):934-941. PubMed ID: 30169681
    [Abstract] [Full Text] [Related]

  • 14. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.
    Eur J Cancer; 2016 Feb 01; 54():69-74. PubMed ID: 26724422
    [Abstract] [Full Text] [Related]

  • 15. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O, Badalato GM, Wosnitzer MS, Hruby G, RoyChoudhury A, Benson MC, Petrylak DP, McKiernan JM.
    Urology; 2012 Feb 01; 79(2):384-90. PubMed ID: 22196406
    [Abstract] [Full Text] [Related]

  • 16. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC.
    Eur Urol; 2015 Feb 01; 67(2):241-9. PubMed ID: 25257030
    [Abstract] [Full Text] [Related]

  • 17. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
    Kawamura N, Matsushita M, Okada T, Ujike T, Nin M, Tsujihata M.
    Hinyokika Kiyo; 2013 May 01; 59(5):277-81. PubMed ID: 23719134
    [Abstract] [Full Text] [Related]

  • 18. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
    Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, Constantinidis C, Hatzimouratidis C, Samantas E, Visvikis A, Chrisophos M, Stravodimos K, Deliveliotis C, Eleftheraki A, Pectasides D, Fountzilas G, Dimopoulos MA.
    Ann Oncol; 2013 Apr 01; 24(4):1011-7. PubMed ID: 23136231
    [Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
    Pal SK, Ruel NH, Wilson TG, Yuh BE.
    Clin Genitourin Cancer; 2012 Dec 01; 10(4):246-50. PubMed ID: 22981208
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.